Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fmed.2021.639970 http://scihub22266oqcxt.onion/10.3389/fmed.2021.639970 34179035!8221239!34179035     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Med+(Lausanne) 2021 ; 8 (ä): 639970 Nephropedia Template TP {{tp|p=34179035|t=2021. Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study |pdf=|usr=}}{{34179035}} gab.com Text Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study JO: Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=34179035 #FOAvip Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of treatment weighting by multinomial propensity scores. Results: Out of 3,451 patients, 33.3% LPV/r and 13.9% received DRV/c. Patients receiving LPV/r or DRV/c were more likely younger, men, had higher C-reactive protein levels while less likely had hypertension, cardiovascular, pulmonary or kidney disease. After adjustment for propensity scores, LPV/r use was not associated with mortality (HR = 0.94, 95% CI 0.78 to 1.13), whereas treatment with DRV/c was associated with a higher death risk (HR = 1.89, 1.53 to 2.34, E-value = 2.43). This increased risk was more marked in women, in elderly, in patients with higher severity of COVID-19 and in patients receiving other COVID-19 drugs. Conclusions: In a large cohort of Italian patients hospitalized for COVID-19 in a real-life setting, the use of LPV/r treatment did not change death rate, while DRV/c was associated with increased mortality. Within the limits of an observational study, these data do not support the use of LPV/r or DRV/c in COVID-19 patients. Twit Text FOAVip Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study ????Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=34179035 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34179035 #FOAvip English Wikipedia <ref>{{Cite pmid|34179035}}</ref> Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study #MMPMID34179035 Di Castelnuovo A; Costanzo S; Antinori A; Berselli N; Blandi L; Bonaccio M; Bruno R; Cauda R; Gialluisi A; Guaraldi G; Menicanti L; Mennuni M; My I; Parruti A; Patti G; Perlini S; Santilli F; Signorelli C; Stefanini GG; Vergori A; Ageno W; Aiello L; Agostoni P; Al Moghazi S; Arboretti R; Aucella F; Barbieri G; Barchitta M; Bartoloni A; Bologna C; Bonfanti P; Caiano L; Carrozzi L; Cascio A; Castiglione G; Chiarito M; Ciccullo A; Cingolani A; Cipollone F; Colomba C; Colombo C; Crosta F; Dalena G; Dal Pra C; Danzi GB; D'Ardes D; de Gaetano Donati K; Di Gennaro F; Di Tano G; D'Offizi G; Filippini T; Maria Fusco F; Gaudiosi C; Gentile I; Gini G; Grandone E; Guarnieri G; Lamanna GLF; Larizza G; Leone A; Lio V; Losito AR; Maccagni G; Maitan S; Mancarella S; Manuele R; Mapelli M; Maragna R; Marra L; Maresca G; Marotta C; Mastroianni F; Mazzitelli M; Mengozzi A; Menichetti F; Milic J; Minutolo F; Molena B; Mussinelli R; Mussini C; Musso M; Odone A; Olivieri M; Pasi E; Perroni A; Petri F; Pinchera B; Pivato CA; Poletti V; Ravaglia C; Rossato M; Rossi M; Sabena A; Salinaro F; Sangiovanni V; Sanrocco C; Scorzolini L; Sgariglia R; Simeone PG; Spinicci M; Trecarichi EM; Veronesi G; Vettor R; Vianello A; Vinceti M; Visconti E; Vocciante L; De Caterina R; Iacoviello L Front Med (Lausanne) 2021[]; 8 (ä): 639970 PMID34179035show ga Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of treatment weighting by multinomial propensity scores. Results: Out of 3,451 patients, 33.3% LPV/r and 13.9% received DRV/c. Patients receiving LPV/r or DRV/c were more likely younger, men, had higher C-reactive protein levels while less likely had hypertension, cardiovascular, pulmonary or kidney disease. After adjustment for propensity scores, LPV/r use was not associated with mortality (HR = 0.94, 95% CI 0.78 to 1.13), whereas treatment with DRV/c was associated with a higher death risk (HR = 1.89, 1.53 to 2.34, E-value = 2.43). This increased risk was more marked in women, in elderly, in patients with higher severity of COVID-19 and in patients receiving other COVID-19 drugs. Conclusions: In a large cohort of Italian patients hospitalized for COVID-19 in a real-life setting, the use of LPV/r treatment did not change death rate, while DRV/c was associated with increased mortality. Within the limits of an observational study, these data do not support the use of LPV/r or DRV/c in COVID-19 patients. äLopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 (epmc).pdf DeepDyve Pubget Overpricing